Pfizer's COVID Drug Data Supports Use in High-Risk Patients: FDA Staff

The US health regulator's staff reviewers said on Tuesday data from Pfizer's COVID-19 drug trials support its use in adults at high risk of progressing to severe disease, bringing the pill closer to a full approval.
Reuters Health Information

source https://www.medscape.com/viewarticle/989613?src=rss

Comments

Popular posts from this blog

RA and RA-ILD Linked to Higher Lung Cancer Risk

New AAFP practice guideline sets blood pressure targets for adults with hypertension

Heart Failure Care Outside of ICU Can Lower Cost